Tumor suppressor miR-215 counteracts hypoxia-induced colon cancer stem cell activity.
Animals
Cell Hypoxia
/ physiology
Colonic Neoplasms
/ genetics
Genes, Tumor Suppressor
Heterografts
Humans
Mice
Mice, Inbred NOD
MicroRNAs
/ genetics
Neoplastic Stem Cells
/ metabolism
Receptors, G-Protein-Coupled
/ genetics
Signal Transduction
Spheroids, Cellular
Tumor Cells, Cultured
Up-Regulation
Colon cancer stem cell
Hypoxia
LGR5
miR-215
microRNA
Journal
Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053
Informations de publication
Date de publication:
28 05 2019
28 05 2019
Historique:
received:
28
11
2018
revised:
08
02
2019
accepted:
14
02
2019
pubmed:
23
2
2019
medline:
6
2
2020
entrez:
22
2
2019
Statut:
ppublish
Résumé
Cancer stem cells, also known as tumor-initiating cells (TICs), are a population of aggressive and self-renewing cells that are responsible for the initiation and progression of many cancers, including colorectal carcinoma. Intratumoral hypoxia, i.e. reduced oxygen supply following uncontrolled proliferation of cancer cells, is thought to support TIC activity by inducing specific hypoxia-responsive mechanisms that are not yet entirely understood. Using previously established and fully characterized patient-derived TIC cultures, we could observe increased sphere and colony formation under hypoxic conditions. Mechanistically, microRNA (miRNA)-profiling experiments allowed us to identify miR-215 as one of the main hypoxia-induced miRNAs in primary colon TICs. Through stable overexpression of miR-215, followed by a set of functional in vitro and in vivo investigations, miR-215 was pinpointed as a negative feedback regulator, working against the TIC-promoting effects of hypoxia. Furthermore, we could single out LGR5, a bona fide marker of non-neoplastic intestinal stem cells, as a downstream target of hypoxia/miR-215 signaling. The strong tumor- and TIC-suppressor potential of miR-215 and the regulatory role of the hypoxia/miR-215/LGR5 axis may thus represent interesting points of attack for the development of innovative anti-CSC therapy approaches.
Identifiants
pubmed: 30790680
pii: S0304-3835(19)30108-9
doi: 10.1016/j.canlet.2019.02.030
pii:
doi:
Substances chimiques
LGR5 protein, human
0
MIRN215 microRNA, human
0
MicroRNAs
0
Receptors, G-Protein-Coupled
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
32-41Informations de copyright
Copyright © 2019 The Author(s). Published by Elsevier B.V. All rights reserved.